FSTL3, follistatin like 3, 10272

N. diseases: 33; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0003850
Disease: Arteriosclerosis
Arteriosclerosis
0.010 Biomarker disease BEFREE All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression. 31815869 2019
CUI: C0004096
Disease: Asthma
Asthma
0.010 Biomarker disease BEFREE To quantify the abundance of the total proteome FSTL3 and activin A in supernatants of differentiated BEC cultures from healthy children and children with asthma, we performed mass spectrometry and ELISA. 29394092 2018
CUI: C0004153
Disease: Atherosclerosis
Atherosclerosis
0.010 Biomarker disease BEFREE All of these results demonstrated that FSTL3 as a novelty cytokine takes part in the process of atherosclerosis through increasing lipid accumulation and inflammation through regulating CD36 and LOX-1 expression. 31815869 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.030 Biomarker disease BEFREE Here we evaluate FSTL3 as a prognostic tool and its relation with clinical and pathological features of breast cancer. 28178680 2017
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.030 Biomarker disease BEFREE We showed that members of the IGF-1/IGFBP-4/PAPP-A axis and FSTL-3 may serve as surrogate markers in breast cancer. 30388235 2019
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma
0.030 Biomarker disease BEFREE Finally, a strong expression of FLRG was observed in invasive breast carcinomas in contrast with the normal luminal epithelial cells in which FLRG was not detected. 17671190 2007
CUI: C1397307
Disease: Cardiac fibrosis
Cardiac fibrosis
0.010 Biomarker disease BEFREE We found that FSTL3 is necessary for this response and for the induction of cardiac fibrosis. 22915069 2012
CUI: C0007222
Disease: Cardiovascular Diseases
Cardiovascular Diseases
0.010 Biomarker group BEFREE We assessed the predictive value of GAL3 (galectin-3), FSTL3 (follistatin-like 3 peptide), and NT-proBNP (N-terminal pro-B-type natriuretic peptide) to identify stage B MHD in young obese participants free of clinically evident cardiovascular disease. 30929550 2019
CUI: C0038454
Disease: Cerebrovascular accident
Cerebrovascular accident
0.010 GeneticVariation group BEFREE Framingham 10-year stroke risk (FSRP-10) quantified CVD-RFs. 30980900 2019
CUI: C1561643
Disease: Chronic Kidney Diseases
Chronic Kidney Diseases
0.010 AlteredExpression group BEFREE Moreover, mFSTL3 mRNA expression was investigated in an animal CKD model, that is, eNOS-/-db/db mice, and compared with littermate controls. 28339962 2017
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.030 Biomarker disease BEFREE In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins. 30842316 2019
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.030 AlteredExpression disease BEFREE Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery. 18617621 2008
CUI: C0018802
Disease: Congestive heart failure
Congestive heart failure
0.030 AlteredExpression disease BEFREE FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown. 22915069 2012
Diabetes Mellitus, Non-Insulin-Dependent
0.010 AlteredExpression disease BEFREE We investigated this hypothesis in humans by studying the physiology of a possible glycaemia-follistatin feedback loop, that is, whether glucose, but not lipid intake (oral or intravenous), can regulate circulating FST and FSTL3 in healthy humans (n = 32), whether the levels of follistatins change in response to various types of bariatric operation in morbidly obese individuals, with or without type 2 diabetes (n = 41), and whether such changes are associated prospectively with improvement of glucose homeostasis/insulin sensitivity. 30393997 2019
CUI: C3839507
Disease: Diminished ovarian reserve
Diminished ovarian reserve
0.010 Biomarker disease BEFREE Forty-eight transcripts were differentially expressed, including CXXC finger protein 5 (CXXC5), forkhead box C1 (FOXC1) (down-regulated in DOR) as well as connective tissue growth factor (CTGF), follistatin-like 3 (FSTL3), prostaglandin-endoperoxide synthase 2 (PTGS2) and suppressor of cytokine signaling 2 (SOCS2) (up-regulated in DOR). 22246450 2012
CUI: C0242339
Disease: Dyslipidemias
Dyslipidemias
0.010 Biomarker group BEFREE FSTL3 as adipokine takes part in dyslipidemia and inflammatory response, but the association of FSTL3 with atherosclerosis is unclear. 31815869 2019
CUI: C0013537
Disease: Eclampsia
Eclampsia
0.010 AlteredExpression disease BEFREE Overproduction of the follistatin-related gene protein in the placenta and maternal serum of women with pre-eclampsia. 17617189 2007
CUI: C0015695
Disease: Fatty Liver
Fatty Liver
0.010 Biomarker disease BEFREE Both FSTL3-knockout and FST288-only mice had extensive hepatic steatosis and elevated hepatic triglyceride content. 23533219 2013
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.020 AlteredExpression phenotype BEFREE Our results suggest that IGFBP1 and Follistatin-like 3 are highly up-regulated in IUGR in the placenta. 16338475 2006
CUI: C0015934
Disease: Fetal Growth Retardation
Fetal Growth Retardation
0.020 Biomarker phenotype BEFREE Microarray experiments identified increased expression of certain genes including leptin, soluble vascular endothelial growth factor receptor, human chorionic gonadotropin, follistatin-like 3, and hypoxia-inducible factor 2alpha in the IUGR. 17240240 2007
CUI: C0085207
Disease: Gestational Diabetes
Gestational Diabetes
0.010 AlteredExpression phenotype BEFREE There were no significant differences in serum FSTL3 levels (p = 0.578) between the GDM group and the GDM-free control group. 27623975 2017
CUI: C0018801
Disease: Heart failure
Heart failure
0.030 Biomarker disease BEFREE In humans, we found that circulating FSTL3 increased with aging, frailty, and HF severity, correlating with an increase in circulating activins. 30842316 2019
CUI: C0018801
Disease: Heart failure
Heart failure
0.030 AlteredExpression disease BEFREE Real-time PCR revealed that FSTL1 and FSTL3 expression was elevated in heart failure but returned to normal after recovery. 18617621 2008
CUI: C0018801
Disease: Heart failure
Heart failure
0.030 AlteredExpression disease BEFREE FSTL3 expression is elevated in patients with heart failure and is upregulated in cardiomyocytes by hypertrophic stimuli, but its role in cardiac remodelling is largely unknown. 22915069 2012
CUI: C0853879
Disease: Invasive carcinoma of breast
Invasive carcinoma of breast
0.010 AlteredExpression disease BEFREE FSTL3 expression in invasive breast cancer is inversely associated with tumor size and nuclear grade but it does not predict disease relapse in the short term. 28178680 2017